Edwards Lifesciences Announces Strategic Investments
March 11, 2019—Edwards Lifesciences Corporation announced strategic transactions involving companies with structural heart disease technologies: Corvia Medical, Inc. and Mitralign, Inc.
Edwards invested $35 million in an exclusive right to acquire Corvia Medical, which developed a transcatheter device designed to treat heart failure with preserved or midrange ejection fraction. The company's interatrial shunt device is designed to provide continuous and dynamic decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure. The therapy has received CE Mark approval in Europe. In the United States, it is being studied as part of an FDA pivotal clinical trial.
Edwards acquired certain assets of Mitralign, including intellectual property and associated clinical and regulatory experience. Mitralign is a developer of an investigational transcatheter annuloplasty system designed to treat functional mitral and tricuspid regurgitation.